培美曲塞与吉西他滨联合卡铂一线治疗晚期非小细胞肺癌的安全性和有效性临床研究

目的分析比较培美曲塞与吉西他滨联合卡铂一线治疗晚期非小细胞肺癌的临床疗效和不良反应，探讨方案的可行性。方法收集我院新院（2011年5月～2012年11月）收治的晚期经病理学证实的非小细胞肺癌患者37例，按治疗方案随机分为两组：A组19例，采用培美曲塞联合卡铂方案；B组18例，采用吉西他滨联合卡铂方案。化疗3周后进行疗效评价及不良反应评价。结果（1）A组ORR及DCR与B组比较差别不大，两组差异无统计学意义（P〉0．05）。（2）A组PFS高于B组，差异有统计学意义（P〈0．05）。1年总生存率与B组比较差异无统计学意义（P〉0．05）。（3）A组副反应发生率低于B组，两组差异有统计学意义（P〈0．05）。结论培美曲塞联合卡铂一线治疗晚期非小细胞肺癌的疗效与吉西他滨联合卡铂的疗效相近，且耐受性较好，患者依从性明显提高，可以推广应用于临床。

Safety and efficacy in clinical studies on pemetrexed and gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer

Objective To compare the clinical efficacy and adverse reactions of the pemetrexed and gemcitabine compared with carboplatin in first-line treatment of advanced non-small cell lung cancer,and explore the feasibility of the program. Methods 37 cases of histologically confirmed advanced non-small cell lung cancer patients were selected from the new hospital（from May 2011 to November 2012）,they were randomly divided into two groups according to the treatment plan： group A included 19 cases,they used pemetrexed and carboplatin; group B included 18 cases, they used gemcitabine and carboplatin. The efficacy and adverse reactions of chemotherapy were evaluated after three weeks. Results （1）There were no significant difference in ORR and DCR between group A and group B（P 〈 0.05）.（2）PFS of group A was higher than group B, the difference was significant（P 〈 0.05）.There were no significant difference in 1-year overall survival between group A and group B（P 〈 0.05）.（3）The side effects rate of group A was lower than group B,the difference was significant（P 〈 0.05）. Conclusion The efficacy of pemetrexed and carboplatin in first-line treatment of advanced non-small cell lung cancer and efficacy of gemcitabine and carboplatin are similar, and well tolerated,can significantly improve patient＇s compliance and can be extended to the clinic.